ANTI-THROMBOCYTIC DRUGS FOR ACUTE CORONARY SYNDROME: DIRECT COMPARISON OF HEMORRHAGIC SAFETY THROMBOCYTE P2Y12-RECEPTOR BLOCKERS TICAGRELOR AND CLOPIDROGEL (BASED ON PLATO STUDY RESULTS
Double anti-platelet therapy (DAPT) comprising a combination of acetylsalicylic acid and one of the thrombocyte P2Y12-receptor blockers is considered an obligatory element of the acute coronary syndrome (ACS) therapy [1–5]. Enlargement of the antiplatelet drugs range with active implementation of ti...
Main Author: | O. V. AVERKOV |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2016-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/1411 |
Similar Items
-
Impact of renal function on Ticagrelor-induced antiplatelet effects in coronary artery disease patients
by: Manuel Veas Porlán, et al.
Published: (2023-06-01) -
Factors Determining Ticagrelor-Induced Dyspnea in Patients with Acute Coronary Syndrome
by: Vytenis Tamakauskas, et al.
Published: (2022-10-01) -
Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
by: Lulu Dai, et al.
Published: (2022-06-01) -
Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy
by: Barry W. Hennigan, et al.
Published: (2022-01-01) -
P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
by: Po-Wei Chen, et al.
Published: (2020-06-01)